86.8%
ELI-004ELI-002cancerin situ immunotherapy
… by anchoring into cell membranes via its lipophilic AMP-tail.1 ELI-004 has been evaluated in multiple phase 1/2 trials (NCT04853017/NC…
1articles mentioning drugs
2drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: ELI-004 ×
ELI-004
This drug is selected. Its supporting articles are shown below.